WO2024241229 - NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER
National phase entry:
Publication Number
WO/2024/241229
Publication Date
28.11.2024
International Application No.
PCT/IB2024/054958
International Filing Date
22.05.2024
Title **
[English]
NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER
[French]
DÉRIVÉS DE NAPHTYRIDINONE POUR LE TRAITEMENT D'UNE MALADIE OU D'UN TROUBLE
Applicants **
NOVARTIS AG
Lichtstrasse 35
4056 Basel, CH
Inventors
CHEUNG, Atwood
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US
LIU, Donglei
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US
PEUKERT, Stefan
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US
TRAUGER, John
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US
Priority Data
63/504,099
24.05.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1558 | |
| EPO | Filing, Examination | 6624 | |
| Japan | Filing | 597 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3910 |
Total: 13264 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates to a compound which is a phosphoric acid ester derivative of a compound of formula (I): (I) wherein A, L and R3 are as described herein, as well as compositions and methods of using such compound.[French]
La présente invention concerne un composé qui est un dérivé d'ester d'acide phosphorique d'un composé de formule (I) : (I) dans laquelle A, L et R3 sont tels que décrits dans la description, ainsi que des compositions et des procédés d'utilisation d'un tel composé.